계산
순이익률 | = | 100 | × | 순수입1 | ÷ | 제품 판매1 | |
---|---|---|---|---|---|---|---|
2023. 12. 31. | 24.96% | = | 100 | × | 6,717) | ÷ | 26,910) |
2022. 12. 31. | 26.42% | = | 100 | × | 6,552) | ÷ | 24,801) |
2021. 12. 31. | 24.25% | = | 100 | × | 5,893) | ÷ | 24,297) |
2020. 12. 31. | 29.97% | = | 100 | × | 7,264) | ÷ | 24,240) |
2019. 12. 31. | 35.32% | = | 100 | × | 7,842) | ÷ | 22,204) |
2018. 12. 31. | 37.25% | = | 100 | × | 8,394) | ÷ | 22,533) |
2017. 12. 31. | 9.08% | = | 100 | × | 1,979) | ÷ | 21,795) |
2016. 12. 31. | 35.27% | = | 100 | × | 7,722) | ÷ | 21,892) |
2015. 12. 31. | 33.13% | = | 100 | × | 6,939) | ÷ | 20,944) |
2014. 12. 31. | 26.69% | = | 100 | × | 5,158) | ÷ | 19,327) |
2013. 12. 31. | 27.93% | = | 100 | × | 5,081) | ÷ | 18,192) |
2012. 12. 31. | 26.11% | = | 100 | × | 4,345) | ÷ | 16,639) |
2011. 12. 31. | 24.08% | = | 100 | × | 3,683) | ÷ | 15,295) |
2010. 12. 31. | 31.56% | = | 100 | × | 4,627) | ÷ | 14,660) |
2009. 12. 31. | 32.09% | = | 100 | × | 4,605) | ÷ | 14,351) |
2008. 12. 31. | 28.57% | = | 100 | × | 4,196) | ÷ | 14,687) |
2007. 12. 31. | 22.12% | = | 100 | × | 3,166) | ÷ | 14,311) |
2006. 12. 31. | 21.29% | = | 100 | × | 2,950) | ÷ | 13,858) |
2005. 12. 31. | 30.56% | = | 100 | × | 3,674) | ÷ | 12,022) |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
1 US$ (백만)
경쟁사와의 비교
Amgen Inc. | AbbVie Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Zoetis Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023. 12. 31. | 24.96% | 8.95% | 17.83% | 19.94% | 15.36% | 21.03% | 41.28% | 0.61% | 3.62% | 30.14% | 13.99% | 27.43% |
2022. 12. 31. | 26.42% | 20.39% | 13.71% | 22.91% | 21.88% | 17.02% | 18.90% | 24.49% | 31.27% | 35.64% | 15.47% | 26.16% |
2021. 12. 31. | 24.25% | 20.54% | 15.08% | 21.84% | 19.71% | 23.05% | 22.26% | 26.79% | 27.04% | 50.25% | 19.70% | 26.20% |
2020. 12. 31. | 29.97% | 10.08% | -21.20% | 16.36% | 25.24% | 0.51% | 17.82% | 14.72% | 22.95% | 41.35% | 19.79% | 24.54% |
2019. 12. 31. | 35.32% | 23.69% | 13.15% | 16.80% | 37.27% | 24.35% | 18.42% | 21.01% | 31.45% | 26.91% | 14.47% | 23.96% |
2018. 12. 31. | 37.25% | 17.36% | 21.81% | 13.33% | 13.16% | 25.16% | 18.75% | 14.71% | 20.79% | 36.42% | 12.06% | 24.52% |
2017. 12. 31. | 9.08% | 18.82% | 4.85% | 13.60% | -0.89% | 18.03% | 1.70% | 5.97% | 40.55% | 20.41% | 10.64% | 16.28% |
2016. 12. 31. | 35.27% | 23.22% | 22.94% | 15.13% | 12.90% | 45.07% | 23.01% | 9.85% | 13.66% | 18.42% | 11.06% | 16.80% |
2015. 12. 31. | 33.13% | 22.50% | 9.45% | 16.33% | 12.07% | 56.32% | 21.99% | 11.25% | 14.25% | 15.50% | 11.64% | 7.11% |
2014. 12. 31. | 26.69% | 8.89% | 12.62% | 13.05% | 12.19% | 49.44% | 21.96% | 28.22% | 18.42% | 12.34% | 11.22% | 12.18% |
2013. 12. 31. | 27.93% | 21.97% | 15.64% | 14.10% | 20.27% | 28.46% | 19.40% | 10.00% | 42.65% | 20.16% | 9.73% | 11.05% |
2012. 12. 31. | 26.11% | 28.70% | 11.12% | 13.10% | 18.09% | 27.57% | 16.14% | 13.05% | 24.70% | 54.43% | 9.42% | 10.06% |
2011. 12. 31. | 24.08% | — | 17.46% | 13.50% | 17.90% | 34.60% | 14.87% | 13.05% | 14.84% | -49.74% | 11.34% | — |
2010. 12. 31. | 31.56% | — | 15.92% | 13.58% | 21.97% | 39.26% | 21.65% | 1.87% | 12.18% | -22.76% | 9.60% | — |
2009. 12. 31. | 32.09% | — | 56.42% | 10.30% | 19.82% | 40.74% | 19.82% | 47.04% | 17.27% | -17.88% | 8.41% | — |
2008. 12. 31. | 28.57% | — | 25.47% | 10.38% | -10.17% | 39.55% | 20.31% | 32.74% | 16.78% | -34.69% | 9.47% | — |
2007. 12. 31. | 22.12% | — | 11.19% | 12.42% | 15.85% | 43.27% | 17.31% | 13.54% | 16.82% | -84.46% | 7.81% | — |
2006. 12. 31. | 21.29% | — | 8.85% | 11.69% | 16.97% | -45.98% | 20.73% | 19.59% | 39.98% | -161.30% | 4.46% | — |
2005. 12. 31. | 30.56% | — | 15.62% | 11.24% | 13.52% | 44.99% | 20.61% | 21.04% | 15.76% | -144.19% | 8.48% | — |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
산업 부문과의 비교: 제약, 생명 공학 및 생명 과학
Amgen Inc. | 제약, 생명 공학 및 생명 과학 | |
---|---|---|
2023. 12. 31. | 24.96% | 17.77% |
2022. 12. 31. | 26.42% | 22.40% |
2021. 12. 31. | 24.25% | 23.35% |
2020. 12. 31. | 29.97% | 13.81% |
2019. 12. 31. | 35.32% | 23.18% |
2018. 12. 31. | 37.25% | 19.48% |
2017. 12. 31. | 9.08% | 13.13% |
2016. 12. 31. | 35.27% | 20.86% |
2015. 12. 31. | 33.13% | 21.21% |
2014. 12. 31. | 26.69% | 21.38% |
2013. 12. 31. | 27.93% | 22.06% |
2012. 12. 31. | 26.11% | 18.54% |
2011. 12. 31. | 24.08% | 15.76% |
2010. 12. 31. | 31.56% | 15.46% |
2009. 12. 31. | 32.09% | 26.03% |
2008. 12. 31. | 28.57% | 18.39% |
2007. 12. 31. | 22.12% | 16.10% |
2006. 12. 31. | 21.29% | 22.37% |
2005. 12. 31. | 30.56% | 18.45% |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).
산업과의 비교: 의료
Amgen Inc. | 의료 | |
---|---|---|
2023. 12. 31. | 24.96% | 8.05% |
2022. 12. 31. | 26.42% | 10.26% |
2021. 12. 31. | 24.25% | 10.89% |
2020. 12. 31. | 29.97% | 7.77% |
2019. 12. 31. | 35.32% | 10.20% |
2018. 12. 31. | 37.25% | 9.25% |
2017. 12. 31. | 9.08% | 7.79% |
2016. 12. 31. | 35.27% | 9.94% |
2015. 12. 31. | 33.13% | 10.96% |
2014. 12. 31. | 26.69% | 11.39% |
2013. 12. 31. | 27.93% | 11.98% |
2012. 12. 31. | 26.11% | 11.18% |
2011. 12. 31. | 24.08% | 10.02% |
2010. 12. 31. | 31.56% | 10.09% |
2009. 12. 31. | 32.09% | 14.33% |
2008. 12. 31. | 28.57% | 10.62% |
2007. 12. 31. | 22.12% | 10.58% |
2006. 12. 31. | 21.29% | 13.20% |
2005. 12. 31. | 30.56% | 12.89% |
보고서 기준: 10-K (보고 날짜: 2023-12-31), 10-K (보고 날짜: 2022-12-31), 10-K (보고 날짜: 2021-12-31), 10-K (보고 날짜: 2020-12-31), 10-K (보고 날짜: 2019-12-31), 10-K (보고 날짜: 2018-12-31), 10-K (보고 날짜: 2017-12-31), 10-K (보고 날짜: 2016-12-31), 10-K (보고 날짜: 2015-12-31), 10-K (보고 날짜: 2014-12-31), 10-K (보고 날짜: 2013-12-31), 10-K (보고 날짜: 2012-12-31), 10-K (보고 날짜: 2011-12-31), 10-K (보고 날짜: 2010-12-31), 10-K (보고 날짜: 2009-12-31), 10-K (보고 날짜: 2008-12-31), 10-K (보고 날짜: 2007-12-31), 10-K (보고 날짜: 2006-12-31), 10-K (보고 날짜: 2005-12-31).